Researchers from Kazakhstan studied the bacterium Helicobacter pylori and found that it exhibits resistance to the drugs amoxicillin and metronidazole. The level of this resistance was 20.98% for amoxicillin and 20.58% for metronidazole, which calls into question the effectiveness of commonly used treatment methods.
The study results were presented on November 20 at an international conference on combating antimicrobial resistance held in Astana. The work emphasizes the need to consider local patterns of antibiotic resistance when treating this infection in Central Asian countries.
The study, titled 'Local Antibiotic Resistance of H. pylori as a Basis for Rational Antimicrobial Therapy in Kazakhstan,' was presented by specialists from the research laboratory of Peter Pospelov Karaganda Medical University. This work was conducted under grant IRN AP19575049 for the period from 2023 to 2025.
The main goal of the scientific project was to assess the sensitivity of H. pylori to antibiotics, identify genetic mechanisms of resistance, and study factors affecting treatment outcomes. Speaking at the conference, one of the researchers noted that Helicobacter pylori poses a problem not only because it causes chronic gastritis and peptic ulcers. Long-term infection with this bacterium is also an established risk factor for stomach cancer.
The International Agency for Research on Cancer (IARC) classifies H. pylori infection as a Group 1 carcinogen. However, the presence of the bacterium in a person does not guarantee the development of cancer.
Antibiotics Showing Resistance
During the study, 110 isolates of H. pylori were analyzed. The E-test method was used to assess the susceptibility of the bacteria to antimicrobial agents. According to the data obtained, resistance to amoxicillin reached 20.98%, while resistance to metronidazole was 20.58%.
Resistance levels for clarithromycin, tetracycline, and rifampicin were 9.8% each. The level of resistance to levofloxacin was lower—4.9%. The study authors considered the resistance to amoxicillin and metronidazole critical, as both indicators exceeded the 20% mark.
The authors called for a review of empirical treatment approaches where antibiotics are prescribed without prior testing of the specific pathogen's sensitivity. They proposed adapting clinical protocols to local data and considering alternative treatment regimens.
Levofloxacin showed the lowest percentage of resistance among the tested drugs, at 4.9%. Researchers suggested that this finding could be taken into account when selecting second-line treatment regimens. However, the authors warned that the results of one study do not automatically imply the prescription of the drug to all patients; treatment decisions must take into account current clinical guidelines, contraindications, and individual patient characteristics.
Genetic Studies Confirm Link Between Mutations and Resistance
In addition to checking antibiotic sensitivity, scientists conducted molecular genetic analysis using polymerase chain reaction (PCR). Mutations in genes associated with resistance to certain drugs, including PBP1, 23S rRNA, rdxA, and 16S rRNA, were studied. The study revealed a statistically significant correlation between certain genetic changes and phenotypic resistance in H. pylori.
Significant results were recorded regarding mutations associated with resistance to amoxicillin, clarithromycin, and metronidazole. The authors noted that molecular tests can facilitate the faster identification of resistant strains and assist doctors in choosing more appropriate therapy regimens.
Risk of Treatment Failure Was 2.43 Times Higher
The researchers also analyzed genetic factors that may affect the effectiveness of eradication therapy aimed at eliminating Helicobacter pylori. According to the results, the presence of the IceA2 genotype was associated with an increased risk of treatment failure. Patients with this genotype had approximately 2.43 times higher chances of unsuccessful cure (odds ratio: 2.429; p = 0.005).
The scientists believe that this genetic marker can be an additional factor in treatment planning.
Prescription Analysis Reveals Problems in Treatment Regimens
The study also included a retrospective analysis of 48 medical records of patients from a clinic in Karaganda in 2023. According to the analysis, dual antibiotic therapy was recorded in 22.9% of cases, metronidazole monotherapy in 25.7%, treatment only with proton pump inhibitors without antibiotics in 39.6%, and bismuth monotherapy in 21.6%.
The presenter clarified that the categories of prescriptions overlapped, leading to the total share exceeding 100%. The researchers concluded that the identified practices indicate a need for stricter control over prescriptions and better adherence to clinical guidelines.
Proposed measures include revising empirical treatment approaches based on local resistance patterns, implementing molecular diagnostics, and improving clinical practice audits.
Significance of Results for Uzbekistan
The work of Kazakhstani scientists highlights the importance of using data on local antibiotic resistance when choosing treatment methods for infections. The sensitivity of Helicobacter pylori to antimicrobial drugs can vary between different regions and countries. Consequently, treatment regimens that do not take into account local epidemiological conditions may be less effective.
For Uzbekistan, these findings are relevant in the context of developing laboratory diagnostics, studying local resistance patterns, and efforts toward rational antibiotic use. However, it is noted that the resistance rates recorded in Kazakhstan cannot be automatically applied to the population of Uzbekistan; local studies are necessary to assess the prevalence of resistant strains.
The study demonstrates how combining laboratory testing of antibiotic sensitivity, molecular genetic methods, and clinical practice analysis can contribute to improving treatment effectiveness.



